| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA777: Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea |
|
Medicine details |
|
| Medicine name | solriamfetol (Sunosi®) |
| Formulation | 75 mg, 150 mg film-coated tablet |
| Reference number | 4434 |
| Indication | To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP) |
| Company | Jazz Pharmaceuticals plc |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 22/01/2020 |
| NICE guidance | TA777: Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea |